This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
12 - 14 Nov 2024
Hamburg Congress CentreHamburg, Germany

Chris Chorley
Associate Director, Global Regulatory CMC, ASO Early Development Lead at Biogen
Speaker

Profile

Chris has worked in the pharmaceutical industry for approximately 15 years, beginning his career as a research scientist for AstraZeneca before moving into regulatory affairs in 2011. He held positions of increasing responsibility with Pharmalink Consulting (latterly Genpact Pharmalink) and Ipsen, before joining Biogen in 2020 where he currently leads the regulatory CMC early development activities for oligonucleotide development programs in Phase 1 and 2. Chris holds a master’s degree in chemistry from the University of York, UK.

Agenda Sessions

  • Regulatory Strategies for Use of Platform Data in Oligonucleotide Development

    14:30